title: [Radioprotective effectiveness of amifostine on the salivary glands of the rat during fractionated irradiation].
abstract: BACKGROUND
  The aim of this study was to evaluate the cytoprotective potency of amifostine during a fractioned irradiation of salivary glands but also on the tumor response of rhabdomyosarcomas R1H in rats.
  
  
  METHODS
  The head-neck-area of male WAG/RijH rats and the tumor in the flank were irradiated with 60Co-gamma-rays (60 Gy/30 f/6 weeks). Amifostine (250 mg/m2) was applicated 15 min before irradiation. The control group was treated with an equal volume of physiologic sodium chloride. The salivary glands were exstirpated and examined histopathologically. Tumour volume was measured, the body-weight of rats determined.
  
  
  RESULTS
  A dose dependent radiosialadenitis developed in all salivary glands. Amifostine had no influence on the response of R1H tumours to radiation. The animal weight loss in the amifostine group was higher as compared to control group.
  
  
  CONCLUSIONS
  No cytoprotective effects on acute toxicity of salivary glands of rats could be detected under irradiation with synchronous application of amifostine. In addition, no effects on tumor response were observed. The general animal constitution decreased by additional medication of amifostine.
authors.affiliation: Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg. christoph.sagowski@gmx.de
authors.forename: C
authors.initials: C
authors.lastname: Sagowski
authors.forename: S
authors.initials: S
authors.lastname: Wenzel
authors.forename: B
authors.initials: B
authors.lastname: Neumann
authors.forename: W
authors.initials: W
authors.lastname: Kehrl
authors.forename: F
authors.initials: F
authors.lastname: Zywietz
authors.forename: K
authors.initials: K
authors.lastname: Roeser
authors.forename: J
authors.initials: J
authors.lastname: Ussmüller
mesh_terms: D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D003037:Cobalt Radioisotopes / Q000009:adverse effects; D019583:Dose Fractionation, Radiation; D008297:Male; D009368:Neoplasm Transplantation; D011833:Radiation Injuries, Experimental / Q000473:pathology / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D011867:Radioisotope Teletherapy / Q000009:adverse effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012208:Rhabdomyosarcoma / Q000473:pathology / Q000532:radiotherapy; D012469:Salivary Glands / Q000473:pathology / Q000528:radiation effects*; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000532:radiotherapy
chemical_list: D003037:Cobalt Radioisotopes; D011837:Radiation-Protective Agents; D004999:Amifostine